Frontlight ResearchEarly access
Taking people in FrancePhase 2
18FET PET scans for hormone-producing pituitary tumors when MRI is unclear
Tests 18FET PET imaging in adults with suspected pituitary tumors and unclear MRI.
Key facts
- Who runs it
- Centre Hospitalier Universitaire De Lille
- Where
- Lille Cedex, FranceSee the site
- Trial code
- Registry title
- Study of 18FET PET in functional pituitary adenomas with indeterminate MRI findings
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 30 people, planned
- Started
- 5 Oct 2026
- Expected to end
- 1 Sept 2030
- Type of study
- Interventional
- Record updated
- 2 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a suspected hormone-making pituitary tumour whose pituitary MRI scan gave an unclear result. They will have an 18FET PET scan.
- Age
- 18 years or older
- Sex
- Male and female
- Disease stage
- Suspected functional pituitary adenoma (prolactinoma, Cushing's disease, acromegaly, thyrotropic adenoma). It can be new, or it can have come back or remained after earlier care. The pituitary MRI result must be unclear.
- Earlier treatment
- People must be able to have surgery and/or radiotherapy if the 18FET PET scan is positive.
Main reasons for not taking part
- Pregnancy
- Known allergy to radioactive tracers (radiopharmaceuticals)
- Active alcohol use
- Liver disease or severe uncontrolled epilepsy
- No social security coverage, people who do not speak French, or people under guardianship
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Male and/or female
- Aged 18 years or older
- Suspected functional pituitary adenoma (prolactinoma, Cushing's disease, acromegaly, thyrotropic adenoma), de novo or recurrence/persistence
- With indeterminate pituitary MRI
- Patient covered by social security
- Patient willing to comply with all study procedures and duration
- Patient eligible for surgery and/or radiotherapy in case of positive 18FET PET scan
Who cannot take part
- Known hypersensitivity to radiopharmaceuticals
- Patients suffering from liver disease or severe uncontrolled epilepsy
- Pregnancy
- Administrative reasons: inability to receive informed consent, inability to participate in the entire study, lack of social security coverage, refusal to sign the consent form
- Patient with active alcohol consumption
- Patients deprived of their liberty (guardianship, curatorship, etc.)
- Patients who do not speak French
This trial is currently available in France.
- Centre Hospitalier Universitaire De LilleLille Cedex, FranceTaking people
About the trial
What the trial wants to find out
Estimate the positivity rate using 18FET PET in patients with de novo, recurrent, or persistent functional AP who are eligible for adenoma-targeted treatment (surgery and/or external beam radiation therapy) and have non-contributory pituitary MRI
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- 18F-fluoro-ethyl-tyrosine (18FET) PET for difficult clinical situations in functional pituitary adenoma. A prospective, single arm, single center study. (FET-PIT)
- Plain-language title
- 18FET PET scans for hormone-producing pituitary tumors when MRI is unclearGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 2 July 2026